Both are weekly injectables that act on gut hormone receptors, but they are not the same molecule. Here is how they differ in mechanism, trial results, side effects and regulatory status.
Semaglutide and tirzepatide are the two most widely prescribed injectable medications for chronic weight management. They are often lumped together as "GLP-1s," and they do share a lot: both are given once a week, both work through gut hormone pathways, and both carry similar warnings. But they are different molecules with different trial records, and a licensed provider may have good reasons to suggest one over the other. This article lays out the differences without recommending either for you.
Semaglutide is a GLP-1 receptor agonist. It activates the receptor for glucagon-like peptide-1, a hormone that increases fullness, slows stomach emptying and improves insulin response after meals.
Tirzepatide activates that same GLP-1 receptor and also the receptor for GIP (glucose-dependent insulinotropic polypeptide), a second gut hormone. Its prescribing information describes it as a dual GIP and GLP-1 receptor agonist. Exactly how GIP contributes to weight reduction is still being studied, but the combination appears to produce larger average effects on body weight than GLP-1 activity alone.
For several years the only way to compare the two was to look at separate placebo-controlled trials, which had different populations and durations. That changed with SURMOUNT-5, a randomized trial published in the New England Journal of Medicine in 2025 that compared the two medications directly.
The trial enrolled 751 adults with obesity and no diabetes across 32 US sites. Participants received the maximum tolerated dose of either tirzepatide (10 or 15 mg weekly) or semaglutide (1.7 or 2.4 mg weekly) for 72 weeks. Average body weight change was -20.2 percent with tirzepatide versus -13.7 percent with semaglutide. Waist circumference fell by an average of 18.4 cm versus 13.0 cm.
Side effects in the trial were mostly mild to moderate gastrointestinal symptoms occurring during dose escalation. Gastrointestinal events leading to discontinuation were somewhat more common with semaglutide (5.6 percent) than with tirzepatide (2.7 percent), although both numbers are low.
Two cautions when reading this. First, the trial was funded by the maker of tirzepatide, which is standard for registration trials but worth knowing. Second, group averages do not describe individuals. Plenty of people respond very well to semaglutide, and some do not tolerate tirzepatide.
Both trials included lifestyle counseling, and both reported that most adverse events were gastrointestinal and concentrated in the dose-escalation period.
Semaglutide has a completed cardiovascular outcomes trial in people without diabetes. SELECT, published in 2023, randomized 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or higher to semaglutide 2.4 mg or placebo. On the basis of that trial, Wegovy's label includes an indication to reduce the risk of major adverse cardiovascular events in that population. Tirzepatide's additional approval is for moderate to severe obstructive sleep apnea in adults with obesity; its cardiovascular outcomes trial in people without diabetes was still ongoing at the time of writing.
The two labels list very similar warnings: a boxed warning about thyroid C-cell tumors observed in rodents, plus cautions about pancreatitis, gallbladder disease, kidney injury from dehydration, severe gastrointestinal reactions, hypersensitivity, diabetic retinopathy complications in people with type 2 diabetes, and aspiration risk during anesthesia. Both are contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
In the Wegovy label, nausea was reported by 44 percent of participants on 2.4 mg (16 percent on placebo), diarrhea by 30 percent, vomiting by 24 percent and constipation by 24 percent. In the Zepbound label, nausea ranged from 25 to 29 percent across doses (8 percent on placebo), diarrhea 19 to 23 percent, vomiting 8 to 13 percent and constipation 11 to 17 percent. Different trial designs make cross-trial comparison unreliable, but gastrointestinal symptoms are common with both and usually ease as the body adjusts.
Both are weekly injections that follow a stepwise escalation schedule managed by the prescriber. We do not publish escalation schedules, because adjusting doses without provider oversight is one of the situations the FDA has flagged in adverse event reports. At Oh My Body Studio, both are priced by dose range because higher doses use more medication; each product page lists the price for every range.
Wegovy and Zepbound are the FDA-approved brand products for chronic weight management. Compounded semaglutide and compounded tirzepatide are prepared by pharmacies and are not FDA-approved. The FDA does not review them for safety, effectiveness or quality, and it has published specific concerns about dosing errors and product handling. The compounded medications available through Oh My Body Studio fall into this category, and we say so plainly on every product page.
That is an incomplete question. Tirzepatide produced larger average weight reductions in the only direct comparison to date; semaglutide has a longer track record and a completed cardiovascular outcomes trial in people without diabetes; side effect categories overlap heavily; and cost and your own health history all weigh on the decision.
A licensed provider can look at your medical history, your other medications and your goals, and explain which option, if any, makes sense. Nothing in this article determines eligibility or replaces that conversation.
This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
GLP-1 medications copy a hormone your gut already makes. Here is what that hormone does, how the medications change appetite and digestion, and which products are FDA-approved versus compounded.
Read articleLosing weight means losing some muscle along with fat. What the research says about how much, why it matters, and the two levers that protect lean mass: protein intake and resistance training.
Read articleNausea, constipation, fatigue and other frequent side effects of GLP-1 medications, what the trial data say about how common they are, and practical strategies people use with their provider's guidance.
Read article